|
|
|
|
|
|
|
|
|
|
|
|
|
Biologics CDMO Selection: Timeline Risks To Watch
|
|
Article | By Ralf Otto, Rezon Bio
|
Choosing a biologics CDMO means planning for timeline risks. Early evaluation of materials, batch release, technical flexibility, transparency, and partnership can help prevent delays.
|
|
|
|
|
|
Prefilled Syringe And Cartridge Filling
|
|
Article | Grand River Aseptic Manufacturing
|
Advanced Fill-Finish Technologies enable precise injectable drug manufacturing, maximizing yield, ensuring compliance, and supporting seamless scale-up from clinical production to commercial supply.
|
|
|
|
|
|
Advancing Animal Health Through Innovative Biologics
|
|
Article | 3PBIOVIAN
|
Partner supporting advanced veterinary biologics with flexible capacity, technical depth, and end‑to‑end capabilities spanning vaccines, recombinant proteins, antibodies, and next‑generation therapies.
|
|
|
|
|
|
|
|
By Louis Garguilo, Chief Editor, Outsourced Pharma
|
Just over a year ago, AstraZeneca went all in on creating a cell-therapy franchise; Samir Panjwani joined as a supplier-relationship manager. “I’ve been a builder throughout my career,” he says. The question he’s always kept in mind: Why are we in this industry? He discusses his new role, and his “bilateral experiences” supporting manufacturing outsourcing supply chains.
|
|
|
|
|
|
|
|
A Conversation with Dr. Maria Elena Bottazzi, Texas Children’s Hospital for Vaccine Development at Baylor College of Medicine
|
Moving infectious disease programs from promising laboratory discoveries to scalable interventions requires bridging the gap between academic research and commercial manufacturing. In this episode of Outsourcing Against the Outbreak, Dr. Maria Elena Bottazzi, Co-Director of the Texas Children's Hospital Center for Vaccine Development at Baylor College of Medicine, explores how academic teams can navigate this journey successfully.
|
|
|
|
|
|
INDUSTRY INSIGHTS CONTINUED
|
|
|
|
|
|
Digital Innovation And Sustainability Are Redefining Biomanufacturing
|
|
White Paper | By Dr. Harald Bradl, and Dr. Fabian Vogt, Boehringer Ingelheim Biopharmaceuticals
|
Next Generation Manufacturing (NGM) integrates advanced process design, digital innovation, and strategic facility planning to facilitate agile, efficient, and sustainable biopharmaceutical production.
|
|
|
|
|
|
|
|
Final Filtration In Chemical Processing
|
|
Application Note | TCP Analytical
|
Ensure chemical product quality with effective final filtration that removes particles and contaminants, boosts efficiency, and meets strict purity requirements across demanding applications.
|
|
|
|
|
|
|
|
Controlling Complexity In ADC Formulation Development
|
|
White Paper | By Eunbi Iris Cho, Ph.D., Samsung Biologics
|
ADC formulation development requires an approach that accounts for the interplay between antibody, linker, and payload, and the stability trade-offs that mAb development experience cannot fully anticipate.
|
|
|
|
|
|
Coordinated Drug Development As An Execution Framework
|
|
White Paper | Thermo Fisher Scientific
|
When clinical research, CMC, manufacturing, and supply operate in silos, every phase transition resets alignment. Read what changes when those functions operate within a shared execution framework.
|
|
|
|
|
|
|
|
Small Is Powerful And Sustained
|
|
Article | Nanoform
|
Advances in sustained-release drug delivery could improve efficiency and consistency in drug release, manifesting real-life advantages for patients in the form of enhanced accessibility and compliance.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Connect With Outsourced Pharma: |
|
|
|
|
